ArticleAmerican journal of cancer research2012
Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy.
Article in American journal of cancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 40 citations in OpenAlex.
- Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).International journal of oncology · 2026Review
- Isorhamnetin from Astragalus membranaceus exerts anti-glioma effects via PI3K/Akt signaling pathway.American journal of cancer research · 2026Article
- Recent advances and future perspectives in small molecule JAK2 inhibitors.Future medicinal chemistry · 2025Review
- Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Exploring the Binding Mechanism of NRG1-ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression.Interdisciplinary sciences, computational life sciences · 2023Article
- Ameliorative Effects of Gut Microbial Metabolite Urolithin A on Pancreatic Diseases.Nutrients · 2022Review
- Toward Development of a Diabetic Synovium Culture Model.Frontiers in bioengineering and biotechnology · 2022Article
- Review
- Costunolide suppresses melanoma growth via the AKT/mTOR pathwayAmerican journal of cancer research · 2021Article
- Juniperus indica Bertol. extract synergized with cisplatin against melanoma cells via the suppression of AKT/mTOR and MAPK signaling and induction of cell apoptosis.International journal of medical sciences · 2021Article
- Cholinergic α5 nicotinic receptor is involved in the proliferation and invasion of human prostate cancer cells.Oncology reports · 2020Article
- Ailanthone Induces Cell Cycle Arrest and Apoptosis in Melanoma B16 and A375 Cells.Biomolecules · 2019Article
- UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway.Cancer management and research · 2019Article
- Identification of key genes in rheumatoid arthritis and osteoarthritis based on bioinformatics analysis.Medicine · 2018Observational
- Defining the Akt1 interactome and its role in regulating the cell cycle.Scientific reports · 2018Article
- Combination of celecoxib (CelebrexAmerican journal of clinical and experimental immunology · 2017Review
- IL-24 modulates the high mobility group (HMG) A1/miR222 /AKT signaling in lung cancer cells.Oncotarget · 2016Article
- HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.Cancer research · 2016Article
- The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction.Oncotarget · 2016Article
- Identification of genes associated with melanoma metastasis.The Kaohsiung journal of medical sciences · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The PI3Kinase/AKT/mTOR signaling module is implicated in various cellular functions including cell survival, growth and proliferation, glucose metabolism, apoptosis, migration, and angiogenesis. Increased expression of AKT and its up- and downstream regulators is linked to several types of cancer. Aberrant expression of AKT is observed in nearly 60% of melanomas culminating in apoptosis resistance via deactivation of apoptotic molecules Bad and Cas-pase-9. Through cross-talk with NF-κB, ERK1/2, JNK and p38MAPK signaling pathways, AKT induces a plethora of cellular effects often leading to tumor development and progression. Due to frequently observed resistance to other common cancer treatments such as chemotherapy, immunotherapy, and radiation, and the detrimental consequences of constitutive activation of the PI3Kinase/AKT/mTOR signaling module, targeted inhibition of the effectors and substrates involved in this module has become a viable and attractive option for molecular targeted therapy in melanoma. Pharmacological inhibitors of various components of this module, either alone or in combination with other agents, have shown significant decrease in proliferation, tumorigenesis, cell growth and survival of various tumors in phases I and II clinical trials. Some inhibitors have even received their Food and Drug Administration (FDA) approval. This review summarizes the current knowledge on this module, its cross-talk with other major cell survival pathways and its targeted inhibition for therapeutic purposes in melanoma.
Indexed as
Identifiers
22485197PMC3304564W154497552What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.